Analytical Data
-
Gene name
AMA-1
- Application
-
Alternative Names
Merozoite surface antigen
-
Species
Plasmodium falciparum
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22621
-
Expression Region
42-73aa&227-271aa&346-407aa&452-488aa&525-546aa
-
Molecular Weight
27.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AMA-1 (Apical Membrane Antigen 1) is a crucial surface protein found on the apical membrane of malaria parasites, particularly Plasmodium falciparum, the most virulent species responsible for malaria in humans. This protein plays a significant role in the invasion of host red blood cells, making it a key target for vaccine development. Research into AMA-1 has gained momentum due to the urgent need for effective malaria vaccines, given the rising resistance to existing antimalarial drugs and the substantial global burden of malaria. AMA-1 has several immunogenic properties, leading to the exploration of its recombinant form as a potential vaccine candidate. Studies have shown that antibodies generated against AMA-1 can inhibit the invasion of malaria parasites into red blood cells, providing a promising immunological basis for its use in vaccine formulations. Furthermore, understanding the structural and functional aspects of AMA-1 aids in identifying immunogenic epitopes that could enhance vaccine efficacy. As a result, the development of AMA-1 recombinant protein vaccines continues to be a focal point in malaria research, with ongoing clinical trials assessing their safety and immunogenicity in various populations. The progression of such research holds significant promise for new malaria control strategies and the eventual goal of malaria eradication.
